Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: The expression of TROP-2 in PSCC tissues and PSCC cells. ( A ) TROP-2 staining in normal tissue and tumor tissue. ( B,C ) TROP-2 protein and mRNA were higher in tumor tissues compared to normal tissues. ( D,E ) TROP-2 expression in different PSCC cell lines. ( F ) The standard staining intensity score of TROP-2 in tumor fissue in the member was no staining was scored with 0, weak staining was scored with 1, moderate staining was scored with 2, and strong staining was scored with 3. ( G ) Proportion of TROP-2 expression in different subgroups. **** p < 0.0001, n.s., No significant. Statistics are expressed as the means ± SDs of three independent experiments. ENE: Extranodal extension; PSCC: Penile squamous cell carcinoma

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: Expressing, Staining

Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: Survival analysis between TROP-2 expression and clinicalopathological factors in PSCC patients. ( A ) Kaplan-Meier survival analysis indicated that high expression of TROP-2 was associated with reduced OS and DFS. ( B ) Survival analyses were also performed in the pT subgroup, ( C ) pN subgroup, and ( D ) the G subgroup. DFS: 5-year disease-free survival; OS: Overall survival

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: Expressing

Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: TROP-2 promotes cell proliferation in PSCC in vitro and in vivo . After being transfected with silencing or over-expressing plasmids, the following experiments were conducted to determine whether TROP-2 affects cell proliferation. ( A ) WB for TROP-2 expression in TROP-2 knockdown/over-express PSCC cells. ( B ) Knockdown and overexpression of TROP-2 in PSCC cells regulate cell proliferation in the CCK-8 experiment in vitro . ( C ) Knockdown and overexpressed of TROP-2 in PSCC cells regulate cell proliferation in the cell colony formation experiment ( D ) and regulate the growth of the tumor in vivo . ( E ) PSCC cells with TROP-2 knockdown exhibit an increased percentage in the G2 phase. ( F ) The knockdown of TROP-2 decreased the G2/M checkpoint proteins expression, such as cdc2 and cyclin B, while G1/S regulators remained unchanged. Significance levels are indicated as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Statistics are presented as the means ± SDs of three independent experiments. NC: Negative control; OE: Overexpression; WT: Wild type

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: In Vitro, In Vivo, Transfection, Expressing, Knockdown, Over Expression, CCK-8 Assay, Negative Control

Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: TROP-2 up-regulated PSCC proliferation through PKCa and AKT pathway. ( A,B ) The GO analysis and heatmap of transcriptome sequencing. ( C ) The expression of protein in the PKCa and AKT pathways in PSCC cells after using PKCa inhibitors. ( D,E ) Cell proliferation was rescued in TROP-2 over-expressed PSCC cells after using PKCa inhibitors. ( F,G ) PSCC cells were arrested in G2/M stage after using PKCa inhibitors. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Statistics are presented as the means ± SDs of three independent experiments. FC: Fold change; OE: Overexpression

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: Sequencing, Expressing, Over Expression

Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: TROP-2 ADC drug shows a significant efficacy in PSCC cells in vivo and in vitro . ( A ) TROP-2 over-expressed PSCC cells showed a lower IC 50 dose to ADC drug than the negative control group. ( B,C ) TROP-2 ADC drug down-regulated the cell proliferation of PSCC cells more significantly in the TROP-2 over-expressed group. ( D–F ) TROP-2 ADC drug also showed better efficacy than cisplatin in TROP-2 over-expressed cells in vivo . **** p < 0.0001. Statistics are presented as the means ± SDs of three independent experiments. IC50: Half maximal inhibitory concentration; OE: Overexpression

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: In Vivo, In Vitro, Negative Control, Concentration Assay, Over Expression

Journal: Oncology Research

Article Title: TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma

doi: 10.32604/or.2025.066184

Figure Lengend Snippet: The toxicity and targeting test of TROP-2 ADC drugs (IMMU-132). IMMU-132 didn’t show serious toxicity to major organs of mice, and its targeting function was also verified. ( A,B ) After injecting PBS, cisplatin or IMMU-132 for 3 weeks, the major organs and blood of mice were obtained. Results of H&E staining and biochemical examinations showed that IMMU-132 didn’t cause obvious toxicity to mice compared with PBS, while cisplatin caused kidney toxicity. ( C ) TROP-2 protein was fixed on the ELISA plate, and different concentrations of IMMU-132 were used to examine its binding ability to TROP-2 protein. ( D ) IMMU-132 was labeled with CY-5 fluorescence. Immunofluorescence was performed at different time points after IMMU-132 was used in TROP-2 OE Penl2 cells. **** p < 0.0001, n.s., No significant. Statistics are expressed as the means ± SDs of three independent experiments

Article Snippet: Given the association of TROP-2 to adverse outcomes and heightened proliferation in PSCC, we performed drug experiments to evaluate the efficacy of the TROP-2 ADC (IMMU-132, MCE) in vivo and in vitro .

Techniques: Staining, Enzyme-linked Immunosorbent Assay, Binding Assay, Labeling, Fluorescence, Immunofluorescence

Journal: Annals of Translational Medicine

Article Title: Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis

doi: 10.21037/atm-21-4257

Figure Lengend Snippet: Specific information on 16 protein targets in the treatment of IGT with TYP

Article Snippet: For example, the expression levels of Rbp4 (boster, #PB0368, China) and Flot2 (boster, #PB0663, China) in the 3 groups were calculated with GAPDH (boster, #BM1623, China) as an internal reference.

Techniques:

Journal: Annals of Translational Medicine

Article Title: Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis

doi: 10.21037/atm-21-4257

Figure Lengend Snippet: Relative expression levels of Rbp4 and Flot2 proteins in pancreatic samples of the 3 groups. Rbp4: *, P<0.05, vs. Control; #, P<0.05, vs. IGT. Flot: *, P<0.05, vs. Control; #, P<0.05, vs. IGT. IGT, impaired glucose tolerance.

Article Snippet: For example, the expression levels of Rbp4 (boster, #PB0368, China) and Flot2 (boster, #PB0663, China) in the 3 groups were calculated with GAPDH (boster, #BM1623, China) as an internal reference.

Techniques: Expressing, Control

Journal: Cancer Imaging

Article Title: Characteristics of 18 F-FAPI-04 PET/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with 18 F-FDG PET/CT

doi: 10.1186/s40644-025-00887-9

Figure Lengend Snippet: Comparison of 18 F-FAPI-04 Uptake Parameters Across FAP-IHC and α-SMA-IHC Score Groups. Bar plots demonstrate significant differences in 18 F-FAPI-04 uptake parameters among groups with FAP-IHC scores 1, 2, and 3 ( A-C ), A : SUV max ; B : T/B; C : T/L. Bar plots show no statistically significant differences in 18 F-FAPI-04 uptake parameters across α-SMA-IHC score groups 1, 2, and 3( D-F ), A : SUV max ; B : T/B; C : T/L

Article Snippet: The expression of FAP and α-SMA in cancer tissues was examined by immunohistochemistry (IHC) using FAP antibody (BOSTER Biological Technology Co., Ltd) or α-SMA antibody (Servicebio Technology Co., Ltd, GB13044), both diluted at 1:200.

Techniques: Comparison

Journal: Cancer Imaging

Article Title: Characteristics of 18 F-FAPI-04 PET/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with 18 F-FDG PET/CT

doi: 10.1186/s40644-025-00887-9

Figure Lengend Snippet: 18 F-FAPI PET/CT imaging and FAP immunohistochemical results (×400, DAB staining) in peritoneal metastases of pancreatic and gastric cancers. A : 18 F-FAPI-04 PET/CT of gastric cancer, B : α-SMA expression in gastric cancer, C : FAP expression in gastric cancer, D : 18 F-FAPI-04 PET/CT of pancreatic cancer, E : α-SMA expression in pancreatic cancer, F : FAP expression in pancreatic cancer. FAP expression in pancreatic cancer was higher than that in gastric cancer

Article Snippet: The expression of FAP and α-SMA in cancer tissues was examined by immunohistochemistry (IHC) using FAP antibody (BOSTER Biological Technology Co., Ltd) or α-SMA antibody (Servicebio Technology Co., Ltd, GB13044), both diluted at 1:200.

Techniques: Positron Emission Tomography-Computed Tomography, Imaging, Immunohistochemical staining, Staining, Expressing